Michael Wang, MD @michaelwangmd of @MDAndersonNews discusses KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL): results of the phase 2 ZUMA-2 study.
CAR T-cell therapy effective for relapsed/refractory MCL #ASH19 @michaelwangmd @MDAndersonNews
